TABLE 1.
Guideline | Recommendation |
---|---|
Number of antiretroviral drugs | HIV PEP regimens should contain three drugs |
Preferred PEP regimen for adults and adolescents | TDF + 3TC/FTC (preferably as fixed-dose combination) is recommended as preferred PEP backbone |
RAL is recommended as preferred third drug for PEP (except in pregnant women, where ATV/r is the recommended third drug) | |
Alternative third drugs include ATV/r, LPV/r, DRV/r or EFV | |
Preferred PEP regimen for children ≤ 35 kg or unable to swallow tablets | AZT + 3TC is recommended as preferred backbone for HIV PEP in children ≤ 35 kg (substitute with d4T if AZT poorly tolerated) |
RAL is recommended as preferred third drug where available for HIV PEP in children. If RAL unavailable, then ATV/r is recommended | |
Prescribing frequency | A full one-month course of antiretroviral drugs should be provided for HIV PEP at initial assessment |
Starter packs should not be used | |
Frequency of follow-up | Exposed individual should be seen at 2 weeks, 6 weeks and 3 months after exposure occurred |
Adherence support | Enhanced adherence counselling is recommended for all individuals initiating PEP |
PEP, post exposure prophylaxis; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine; RAL, raltegravir; ATV/r, atazanavir/ritonavir; LPV/r, lopinavir/ritonavir; DRV/r, darunavir + ritonavir; EFV, efavirenz; AZT, zidovudine.